Processes for the production of tryptamines
Disclosed herein are prokaryotic and eukaryotic microbes, including E. coli and S. cerevisiae , genetically altered to biosynthesize tryptamine and tryptamine derivatives. The microbes of the disclosure may be engineered to contain plasmids and stable gene integrations containing sufficient genetic information for conversion of an anthranilate or an indole to a tryptamine. The fermentative production of substituted tryptamines in a whole-cell biocatalyst may be useful for cost effective production of these compounds for therapeutic use.
1. A composition comprising:
(a) an engineered microbial cell containing therein one or more heterologous nucleic acid sequences encoding one or more of:
(i) a tryptamine 4-hydroxylase comprising an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOS: 32-35;
(ii) a tryptamine 5 -hydroxylase comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 47;
(iii) a kinase comprising an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOS: 41-44;
(iv) a P450 reductase comprising an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOS: 36-40; and
(v) a transferase comprising an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOS: 21-31 or 46; and
(b) a tryptamine derivative,
wherein the engineered microbial cell converts a substituted tryptamine to the tryptamine derivative, wherein the tryptamine derivative is:
2. The composition of claim 1 , wherein the engineered microbial cell is a eukaryotic cell.
3. The composition of claim 2 , wherein the eukaryotic cell is a yeast cell.
4. The composition of claim 3 , wherein the yeast cell is of the species Saccharomyces cerevisiae.
5. The composition of claim 1 , wherein the engineered microbial cell is a prokaryotic cell.
6. The composition of claim 5 , wherein the prokaryotic cell is a bacterial cell.
7. The composition of claim 6 , wherein the bacterial cell is of the species Escherichia coli or Corynebacterium glutamicum.
8. The composition of claim 1 , wherein the substituted tryptamine is produced biosynthetically by the engineered microbial cell.
9. The composition of claim 1 , wherein the engineered microbial cell secretes the tryptamine derivative into a culture broth.
10. The composition of claim 1 , wherein the engineered microbial cell is a lysate of the engineered microbial cell.